Class I reimbursement was granted to Octreoscan in Belgium.
Octreoscan imaging agent is a unique molecular imaging agent for the scintigraphic localization of primary and metastatic neuroendocrine tumors bearing somatostatin receptors.
The agent is uniquely targeted for identification of neuroendocrine tumors bearing somatostatin receptors.
Octreoscan imaging agent is highly sensitive for a variety of primary neuroendocrine tumors and metastases.
It provides valuable clinical information to support the diagnosis and selection of a treatment plan.